Jade Biosciences Inc SEC Filings

On July 14, 2025, Jade Biosciences, Inc. (ticker JBIO) filed a Form 4 disclosing that its Chief Financial Officer, Bradford D. Dahms, received a new equity award.

• Security granted: Stock option covering 526,000 shares of common stock.
• Exercise price: $9.00 per share.
• Term: Expires on July 14, 2035 (10-year term).
• Vesting schedule: 25 % vests on July 14, 2026; the remaining 75 % vests in equal monthly installments over the following three years, contingent on continued employment.
• Ownership form: Direct.

No common stock was bought or sold; the filing strictly reports the compensatory option grant. The transaction could increase potential dilution by up to 526,000 shares if fully exercised, but its materiality depends on JBIO’s total shares outstanding, which is not provided in this filing.

Jade Biosciences, Inc. (NASDAQ: JBIO) filed an 8-K announcing two material events:

• Patheon Master Services Agreement (Item 1.01): On 26 June 2025 the company entered into a five-year, automatically renewable master services agreement with Patheon Biologics (Thermo Fisher). Patheon will provide cGMP development, manufacturing and testing for lead asset JADE101 and future programs on a non-exclusive, project-by-project basis. Key protections include IP assignment to Jade, notification of regulatory inspections and the right for Jade to cancel projects (subject to customary fees). Financial terms are project-specific and not disclosed, but the agreement secures commercial-scale capacity and regulatory-compliant manufacturing know-how.
• C-suite transition (Item 5.02): Bradford Dahms, age 37, will become Chief Financial Officer & Treasurer effective 14 July 2025. His compensation package comprises a $500,000 base salary, a 40 % target bonus and an option for 526,000 shares vesting over four years. Change-in-control protection provides up to 1.5× salary plus target bonus and full vesting acceleration. Mr. Dahms previously held CFO roles at IDRx, Theseus Pharmaceuticals and Selecta Biosciences, bringing deep capital-markets and business-development expertise. Incumbent SVP Finance Jonathan Quick remains with the company but relinquishes principal accounting officer duties.

Collectively, the Patheon MSA de-risks manufacturing for the clinical pipeline, while the seasoned CFO hire strengthens financial leadership ahead of potential late-stage development and capital-raising activities.

Form 144 Notice of Proposed Sale filed by Jade Biosciences indicates a planned sale of 28,977 shares with an aggregate market value of $303,678.96 through Merrill Lynch on the Nasdaq exchange, scheduled for June 25, 2025.

The securities were originally acquired through a Private Placement from the issuer on June 4, 2021, purchased with cash. The total outstanding shares are 28,985,019.

Recent Trading Activity:

• Atlas Ventures Fund XII LP and Atlas Ventures Associates XII LP have conducted multiple sales in the past 3 months
• Most recent transactions occurred June 24-25, 2025, with Atlas Ventures Fund XII LP selling 16,132 shares ($167,776.03)
• Total combined recent sales by Atlas entities amount to approximately 22,429 shares

Form 144 Notice of Proposed Sale filed by Jade Biosciences (NASDAQ: JBIO) on June 28, 2025, detailing planned insider stock sales. The filing indicates a proposed sale of 235 shares with an aggregate market value of $2,462.80 through Merrill Lynch, representing a small portion of the total 28,985,019 shares outstanding.

Key transaction details:

• Shares were originally acquired through Private Placement on June 4, 2021
• Planned sale date: June 25, 2025
• Current market price implies approximately $10.48 per share

Recent insider selling activity by Atlas Ventures entities in the past 3 months totals 51,171 shares for aggregate proceeds of $537,316.10, including significant sales by Atlas Ventures Fund XII LP (50,992 shares) and smaller transactions by Atlas Venture Associates XII, LP (179 shares). This Form 144 filing suggests continued insider selling pressure while affirming no knowledge of undisclosed material adverse information.

Jade Biosciences (NASDAQ: JBIO) has filed a Form 144 notice indicating a proposed sale of 16,132 shares with an aggregate market value of $159,222.84. The securities are to be sold through Merrill Lynch, with the planned transaction date of June 24, 2025.

The shares were originally acquired through a Private Placement from the issuer on June 4, 2021, with cash payment. The total outstanding shares of the company are 28,985,019.

Recent insider trading activity includes:

• Atlas Ventures Fund XII LP sold 5,883 shares for $64,061.73 on May 6, 2025
• Atlas Ventures Associates XII LP made two sales: 48 shares for $498.84 on May 6, 2025, and 131 shares for $1,292.97 on June 24, 2025

This Form 144 filing represents the declaration of intention to sell restricted securities, as required by SEC Rule 144 under the Securities Act of 1933.

Form 144 Notice of Proposed Sale filed by Atlas Ventures for Jade Biosciences (NASDAQ: JBIO) indicates planned insider stock sales. The filing details a proposed sale of 131 shares at an aggregate market value of $1,292.97 through Merrill Lynch, with execution planned for June 24, 2025.

Key transaction details:

• Shares were originally acquired through private placement on June 4, 2021
• Current total shares outstanding: 28,985,019
• Recent related sales in past 3 months:
  • Atlas Ventures Fund XII LP: 5,883 shares ($64,061.73) on May 6, 2025
  • Atlas Venture Associates XII LP: 48 shares ($498.84) on May 6, 2025
  • Atlas Ventures Fund XII LP: 16,132 shares ($159,222.84) on June 24, 2025

The filing indicates no knowledge of material adverse information regarding Jade Biosciences' operations that hasn't been publicly disclosed.